Travere CEO Eric Dube to step down
Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will step down.
Travere Therapeutics
NASDAQ: TVTX $59.83 USD
Biopharmaceutical company focused on identifying, developing and commercializing therapies for rare diseases, with an emphasis on rare kidney and metabolic conditions; markets FILSPARI (sparsentan) for IgA nephropathy.
Company Info
Upcoming Milestones & Key Dates
2026-12-01
Leadership
Bradley Campbell succeeds Eric Dube as CEO
2027-02-15
Leadership
Eric Dube's executive advisor term ends
Clinical Development Pipeline
FILSPARI (sparsentan)
Target: Dual endothelin and angiotensin II receptor antagonistpegtibatinase
Target: Cystathionine beta-synthase (CBS) enzyme replacementRecent News
Leadership Team
Eric Dube, Ph.D.
Chief Executive Officer (stepping down; remains executive advisor through February 2027)
Bradley Campbell
Chief Executive Officer, effective December 1, 2026